Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitec...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Francesca Matilde Schipilliti, Denise Drittone, Federica Mazzuca, Daniele La Forgia, Deniz Can Guven, Alessandro Rizzo
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Elsevier 2024-04-01
Cyfres:Heliyon
Pynciau:
Breast cancer
Triple-negative breast cancer
ADC
Antibody-drug conjugates
Dato-DXd
Datopotamab deruxtecan
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2405844024044165

Rhyngrwyd

http://www.sciencedirect.com/science/article/pii/S2405844024044165

Eitemau Tebyg